Form 4: Verve Therapeutics Director Jodie Pope Morrison Granted 42,200 Stock Options

Verve Therapeutics, Inc. director Jodie Pope Morrison was granted 42,200 stock options with an exercise price of $5.73 as part of the company's director compensation program.

Summary

• Jodie Pope Morrison, a Director of Verve Therapeutics, Inc. (VERV), acquired 42,200 stock options.
• The transaction date for this acquisition was June 5, 2025.
• Each stock option has an exercise price of $5.73.
• The options were granted pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. and its director compensation program.
• The vesting commencement date is the grant date (June 5, 2025).
• All shares underlying the option vest upon the earlier of the one-year anniversary of the vesting commencement date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options expire on June 4, 2035.
• Following this transaction, Jodie Pope Morrison beneficially owns 42,200 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the transaction represents a routine compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their long-term interests with those of the shareholders, incentivizing performance and value creation.
• The transaction is part of a pre-existing, approved compensation plan (2021 Stock Incentive Plan), indicating structured corporate governance.

Future Outlook

The vesting schedule of the stock options, tied to continued service as a director, indicates an expectation of Jodie Pope Morrison's ongoing contribution to the company's governance and strategic direction.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive and director compensation packages to attract and retain talent and align interests with company performance.

Comparison to Industry Standards

• The structure of this director compensation, involving stock options with a vesting schedule, is consistent with typical compensation practices for board members in publicly traded biotechnology companies.
• While specific comparable companies are not mentioned in the filing, similar equity-based compensation plans are prevalent across the sector to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• Issuance of 42,200 stock options to Jodie Pope Morrison, a director of Verve Therapeutics, Inc., as part of the company's approved director compensation program.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Jodie Pope Morrison's continued service as a director for the options to vest.
• The options will vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders after the grant date.

Key Dates

Keywords

Verve Therapeutics, VERV, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Form 4, Beneficial Ownership